Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Receivables (2017 - 2025)

Neurocrine Biosciences' Receivables history spans 16 years, with the latest figure at $707.3 million for Q4 2025.

  • For Q4 2025, Receivables rose 43.32% year-over-year to $707.3 million; the TTM value through Dec 2025 reached $707.3 million, up 43.32%, while the annual FY2025 figure was $707.3 million, 43.32% up from the prior year.
  • Receivables reached $707.3 million in Q4 2025 per NBIX's latest filing, down from $728.0 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $728.0 million in Q3 2025 to a low of $151.0 million in Q1 2021.
  • Average Receivables over 5 years is $399.7 million, with a median of $411.0 million recorded in 2023.
  • Peak YoY movement for Receivables: fell 1.5% in 2021, then skyrocketed 88.97% in 2022.
  • A 5-year view of Receivables shows it stood at $187.7 million in 2021, then soared by 88.97% to $354.7 million in 2022, then increased by 27.01% to $450.5 million in 2023, then grew by 9.54% to $493.5 million in 2024, then soared by 43.32% to $707.3 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Receivables are $707.3 million (Q4 2025), $728.0 million (Q3 2025), and $595.7 million (Q2 2025).